Dr. Mikhail Blagoskloony is a scientist who studies aging and cancer. He earned his M.D in internal medicine and his PhD in external medicine from the First Pavlov State Medical University of St. Petersburg. In 2002, he was appointed associate professor of medicine at New Your Medical College. Shortly thereafter he accepted a position as senior scientist at Ordway Research Institute. Since 2009 Dr. Mikhail Blagoskloony is working as a professor of Oncology at Roswell Park Cancer Institute in New York. View his LinkedIn profile
Dr. Blagoskloony formulated a hypothesis about the possible role of TOR (Target of rapamycin) signaling in aging and cancer by the use of rapamcyin, a cancer drug as a possible treatment for life extension. In on words, it would be an anti-aging drug that would slow or reverse aging. While Dr. Blagoskloony was working on cancer patients, he realized that the same qualities that made rapamycin effective at slowing tumor growth, would possibly slow aging as well. In fact the doctor even takes rapamcyin himself.
His role as professor of Oncology at Roswell Park Cancer Institute in New York is to help facilitate the development of new anti-cancer strategies and development and methods of cancer protection that are not limited to: therapy, selective combination anticancer drugs, and prevention of cancer by slowing down organismal aging. of In addition to Mikhail Blagoskloony’s groundbreaking work in his field he is Founding Editor and Editor-in-Chief for Cell Cycle and Associate Editor of the following publications: PLOS ONE, Cancer Biology & Therapy, American Journal of Pathology, Cell Death & Differentiation, Autophagy, Cancer Research, and International Journal of Cancer. Follow Mikhail on Loop